by binding to their cognate receptors, which are members of the nuclear receptor superfamily (reviewed in Beato, 1989; Mangelsdorf et al., 1995) . These receptors serve as molecular targets for treatment of such cancers by steroid antagonists such as the antiestrogen tamoxifen, and the mechanism by which activated receptors regulate cell proliferation and tumor growth continues to unfold, sometimes in unexpected ways. This review will concentrate on the estrogen (ER) and progesterone (PR) receptors, which serve critical roles in several types of cancer, particularly for breast tumors (Sutherland et al., 1998) . In the absence of the physiological ligand, 17b-estradiol (E2) ER is thought to reside primarily in the nucleus, with a small proportion of receptor in the cytoplasm, whereas a larger proportion of PR is cytoplasmic. Increased ER and PR nuclear localization occurs in the presence of ligand. The receptors act as dimers that bind to DNA at specific target sequences called estrogen and progesterone response elements (EREs or PREs) present in the promoter regions of responsive genes (Beato, 1989) . The receptor acts as a ligand-activated transcription factor, and hormone binding initiates changes in gene transcription, resulting in changes in levels of target gene mRNA and translated protein.
All members of this superfamily have a similar modular protein structure (Figure 1 ). Two functions, that of DNA binding and hormone binding, are contained entirely within central and C-terminal regions, respectively. Other functions, including nuclear localization, dimerization, and transcriptional activation, or 'transactivation', require cooperation between regions of the receptor for full activity. For example, dimerization motifs are present in both the DNAbinding and ligand-binding domains (DBD and LBD) . In addition, full transcriptional activity requires both the ligand-dependent activation function-2 (AF2) domain in the C-terminus and the ligand-independent AF1 activity in the N-terminus. The contribution of each region to hormone-stimulated transcription is cell type and promoter dependent (reviewed in Mangelsdorf et al., 1995) .
There are two closely related isoforms for both ER and PR (Figure 1 ). ERa and ERb are transcribed from two separate genes on different chromosomes, and are expressed in both separate and overlapping tissues and cell types (Kuiper et al., 1996 . There is near identity between the two proteins in the DBD, over 50% homology in the LBD, but great divergence in the Ntermini of the proteins. Both ERs act through the same general mechanism in target cells, with ERb less transcriptionally active, but there are some distinct biological actions on specific gene promoters and in response to synthetic ligands . ERa is more highly expressed and may play the major role in steroid-dependent cancers of the breast and uterus (Jordan et al., 1988; Ricketts et al., 1991; Jazaeri et al., 2001; Fuqua et al., 2003; Pearce and Jordan, 2004) . ERb is preferentially lost in uterine, colon, and ovarian cancer, and the introduction of ERb slows the growth of breast cancer cells (Foley et al., 2000; Jazaeri et al., 2001; Paruthiyil et al., 2004; Strom et al., 2004) . These data have led to the intriguing hypothesis that the loss of ERb contributes to development of cancer or that the level of ERb influences estrogen-stimulated tumor growth, but this idea requires additional documentation in both laboratory and clinical settings. ERb levels are just beginning to be measured in breast tumors, and do not appear to correlate directly with ERa levels, but the usefulness of ERb as a prognostic indicator has yet to be determined (Fuqua et al., 2003) . The PR exists as either longer PR-B (120 kDa) or N-terminally truncated PR-A (97 kDa) forms that are transcribed from separate promoters on the same gene, and both proteins appear to be expressed in most target tissues (reviewed in Lange, 2004) . PR-B contains an additional activation function (AF3) that is located in the extended Nterminal region, and is generally less transcriptionally active than PR-A (Sartorius et al., 1994; Norris et al., 1997) .
Steroid actions on transcription
Crystallographic studies show that the LBD of the steroid receptors consists of a hollow ball of alpha helices, and that hormone binding in the interior pocket causes a reorganization of the helices and a change in protein conformation (Shiau et al., 1998) . This allows recruitment of proteins called coactivators via specific LXXLL motifs in the coactivators (reviewed in Westin et al., 2000) . The steroid receptor-ligand-coactivator complex then recruits integrator proteins such as CREB binding protein, or CBP, which by DNA looping brings the receptor-containing regulatory region of the gene into proximity with the actual transcriptional start site (Gothard et al., 1996; Chen et al., 1999) . Both CBP and some of the coactivator proteins have histone acetylase activity, which modifies the histones and forces the chromatin surrounding the genes into a more open conformation to increase access of RNA polymerase and gene transcription (Chen et al., 1999; Shang et al., 2000) . Antisteroid compounds like tamoxifen prevent steroid action by inducing a conformation in the ligandbinding pocket that fails to bind coactivators, thus preventing the recruitment of CBP and transcriptional activation, and allowing the recruitment of corepressor proteins that contain active corepressor domains, or recruit histone deacetylase activity (Shiau et al., 1998; Shang et al., 2000) . Steroid-regulated promoters recruit the ligand-bound receptors and regulatory proteins in an ordered, cyclical manner (Shang et al., 2000; Metivier et al., 2003; Reid et al., 2003) . This process appears to be linked with proteasome activity and receptor and coregulatory protein degradation for maximal ligandstimulated transcription, but the absolute requirement for proteasomal activity for steroid receptor-mediated transcription remains under investigation (reviewed in Nawaz and O'Malley, 2004) .
In addition to binding to 'classical' ERE and PRE motifs, both ER and PR can stimulate gene transcription without binding to DNA by associating with other transcription factors bound to promoters of responsive genes. Genes stimulated in the absence of canonical PREs or EREs include important physiological targets such as cyclin D1, p21, and the E2-sensitive PR promoters (Schlegel et al., 1999; Petz and Nardulli, 2000; Petz et al., 2002 ). An increasing number of steroidresponsive genes have been identified that are regulated via ER interactions with Sp1 (Stoner et al., 2004) , the signal transducers and activators of transcription (STAT) family of transcription factors (Faulds et al., 2001 (Faulds et al., , 2004 and proteins on AP1 sites (Kushner et al., 2000) , as well as by PR interactions with AP-1 binding proteins (Bamberger et al., 1996) . There is some isoform selectivity for these responses, as only ERa can stimulate genes via the Sp1 pathway (Saville et al., 2000) , and the two ER isoforms are differentially regulated by E2 and antiestrogens at AP1 sites (Paech et al., 1997 In reproductive tissues such as uterus and breast, estrogen, IGF-1, and EGF are all mitogenic, and may play an important role in the growth of tumors in these tissues. It has become increasingly clear that in these tissues the steroid and growth factor pathways interact at several levels. Furthermore, full proliferative responses may require function of both signaling pathways.
EGF-R crosstalk with ER and PR
In mouse uterus, treatment with anti-EGF antibodies attenuates the uterine proliferative response to E2; conversely, administration of the ER antagonist ICI 164,384 reduces the response to EGF (Ignar-Trowbridge et al., 1992 , 1993 . Similar observations have been made in the mammary gland (Ankrapp et al., 1998) , and at least part of this biological cooperation may occur because E2 can induce the synthesis and secretion of EGF (Dickson et al., 1986) . However, studies in ERaknockout mice demonstrated that EGF could no longer induce transcription or DNA synthesis in the uterus, even in the presence of wild-type levels of EGF and EGF-R and a functional EGF signaling system (Curtis et al., 1996) . In EGF-R knockout mice, the E2 response in stromal but not epithelial cells of the uterus and vagina is severely limited (Hom et al., 1998) . These studies suggest that there is a true requirement for ERa protein for EGF-mediated growth, at least in the uterus. In uterine cells, progesterone does not cause proliferation and can in fact antagonize the proliferative effects of E2 during the secretory phase of the menstrual cycle. In breast cancer cells, progestins both stimulate and inhibit cell cycle progression, while increasing expression of transforming growth factor, EGF-R, c-fos, and c-myc genes (Sutherland et al., 1998) . Progestin treatment has been shown to potentiate the effects of EGF by upregulating type I tyrosine kinase receptors of the EGR or HER family, including EGFR, c-erbB2 and cerbB3 receptors (presumably by genomic mechanisms), and by enhancing EGF-stimulated tyrosine phosphorylation of signaling molecules known to associate with activated type I receptors (reviewed in Lange, 2004) .
IGF1-R crosstalk with ER and PR
There is increasing evidence that there are also significant functional interactions between ERa and the IGF-1R and its signaling pathways in breast and uterine cells. IGF-1 stimulates mitogenesis of the normal epithelium and proliferation of both endometrial cancers and leiomyoma cells (Strawn et al., 1995; Klotz et al., 2000) . In the mouse uterine model, the in vivo proliferative response of IGF-1 requires ERa, even in the presence of a functional IGF-1 signaling response, as IGF-1 signaling to MAPK or Akt is unaffected by the loss of ER (Klotz et al., 2002) . In the uterus, E2 increases the levels of IGF-1 mRNA, and stimulates tyrosine phosphorylation of the IGF-1 receptor and insulin receptor substrate-1, and the formation of IGF-1R signaling complexes (Richards et al., 1996; Klotz et al., 2000) . In breast cancer cells, IGF-1 and E2 cooperate to promote G1/S cell cycle progression (Adesanya et al., 1999) . E2 rapidly stimulates IGF1-R phosphorylation, while an inhibitor of IGF-1R phosphorylation blocks E2-induced breast cancer cell proliferation (Kahlert et al., 2000; Song et al., 2004) .
Ligand-independent activation of steroid receptors through growth factor pathways During the past several years, many investigators have documented that crosstalk between steroid-and growth factor-stimulated intracellular signaling pathways can directly impact the function of steroid receptors and the transcription of steroid receptor-regulated genes (reviewed in Edwards et al., 1993; Weigel and Zhang, 1999; Lange, 2004) . One mechanism by which this occurs is by direct phosphorylation of ER and PR proteins, coactivators and other regulatory proteins to make steroid receptor-mediated transcription more effective. Both ER and PR isoforms are phosphoproteins, and specific serine residues are phosphorylated basally and in response to ligands, growth factors and other regulatory molecules via MAPK, Rsk, PKA, PKC, casein kinase II and CDK2 (reviewed in Edwards et al., 1993; Weigel and Zhang, 1999; Lannigan, 2003; Lange, 2004) . The biological significance of all the phosphorylations is not known; however, a few specific sites have been demonstrated to play important roles in receptor activity in response to growth factor tyrosine kinase receptor activation ( Figure 1 ).
ER phosphorylation and ligand-independent activation of transcription
Serine 118 in the AF1 of ERa was first described as a direct target of epidermal growth factor (EGF)-stimulated pathways via ras and MAPK activation. Phosphorylation of this residue in cells that allow expression of AF1 activity activates the receptor in the absence of ligand, and stimulates both translocation of the receptor to the nucleus and transcription of transfected reporter genes (Kato et al., 1995; Bunone et al., 1996) . Mutation of this residue to alanine eliminates the activated ras and growth factor effects. An analogous residue (Ser60) in the mouse ERb is similarly modified in response to rasactivated pathways (Tremblay et al., 1997) , and MAPK phosphorylation of Serines at 106 and 124 (Ser 87 and 105 in human ERb) are also postulated to play a critical role in ligand-independent activation (Tremblay et al., 1999) . Coregulatory proteins such as steroid-receptor coactivator-1 (SRC-1) and amplified in breast cancer-1 (AIB1) are also phosphorylated in response to growth factors, and overall ligand-independent ER activation may be due to more efficient recruitment of coactivators to the N-termini of the ERs after EGF treatment (Tremblay et al., 1999; Font de Mora and Brown, 2000; Dutertre and Smith, 2003) . In response to serum and EGF, ERa is also phosphorylated at Serine167 by a pathway that requires the enzyme Rsk rather than MAPK, and includes a physical association of this enzyme with the LBD of ERa (Joel et al., 1998; Clark et al., 2001) . Enzyme docking and transcriptional activation through this pathway is specific for ERa and do not occur with ERb. EGF and insulin-like growth factor-1 (IGF-1) also stimulate ERa transcriptional activity in breast cancer cells via the Akt/PI3K pathway, by phosphorylation of serines 104/106/118/167 (Martin et al., 2000) . EGF stimulation of ERa transcription via Akt, MAPK and Rsk is correlated with increased receptor turnover, as for ligand-dependent transcription (Joel et al., 1998; Martin et al., 2000; Lannigan, 2003) . However, increased ER transcriptional activity correlated with increased ER turnover via the proteasomal pathway is not consistent among all signaling pathways for ligandindependent activation, as PKA stabilizes the receptor and pharmacological inhibitors differentially affect proteasome-mediated stability and transcription (Marsaud et al., 2003; Tsai et al., 2004) . E2-dependent and ligand-independent transcriptional activation of the ERs through protein kinases activated by growth factor pathways are synergistic (Cho and Katzenellenbogen, 1993) . In addition, MAPK activation renders ERa hypersensitive to lower levels of E2 (Jeng et al., 1998; Shim et al., 2000) and more sensitive to proliferative actions of E2 (Yue et al., 2002) Progesterone receptor phosphorylation and ligand-independent activation of transcription Both PR-A and PR-B are phosphorylated at equivalent sites under basal conditions, and in response to ligand binding and growth factor signaling cascades (Figure 1, reviewed in Weigel and Zhang, 1999; Lange, 2004) . In response to growth factors such as EGF, Ser294 of PR-B is rapidly (3-5 min) phosphorylated via a MAPKdependent pathway . Phosphorylation of this residue is critical for EGF-, but not ligandmediated, nuclear localization of the receptors in several cell types, including HeLa and breast cancer cells . Heregulin, which binds several members of the HER family of receptor tyrosine kinases, has been reported to stimulate PR-B Ser294 phosphorylation, nuclear localization, DNA binding, and transcriptional activity in the absence of progesterone in T47D breast cancer cells (Labriola et al., 2003) . These events required the c-erbB-2/HER2 receptor and were coupled with MAPK activation. Other investigators, using T47D cell variants, found that Ser294 phosphorylation was required for transcriptional synergy between growth factors and progesterone and for ligand-induced receptor degradation via the ubiquitin-proteasome pathway (Lange et al., 2000; Shen et al., 2001) . In these studies, however, growth factors alone could not stimulate PR transcriptional activity or downregulate PR levels (Shen et al., 2001) . It has been suggested that differential expression of EGF receptor family members (EGF or HER1, HER2/cerbB2/neu, HER3/c-erbB3, and HER4/ c-erbB4) between these cell lines, leading to differential activation of intracellular signaling cascades, might contribute to these differences in the ability of growth factors to activate the PR (Lange, 2004) . Like ER, the phosphorylated PR has increased sensitivity to lower levels of ligand , and EGF and progesterone treatment of breast cancer cells synergistically stimulate expression of genes such as cyclin D1 and E that are critical for proliferation . Because breast tumors often have elevated levels of MAPK activity (Salh et al., 1999) , activation of ERs and PRs independent of ligands could occur in these cancers, contributing to receptor-stimulated gene expression and cell growth even in the absence of steroids.
Novel actions of estrogen and progesterone originating outside the nucleus
Over the past decade, there has been increasing appreciation that E2 and progestins may rapidly stimulate many cellular activities, some of which use signaling pathways in common with tyrosine kinase receptors like the EGF-R family members (reviewed in Segars and Driggers, 2002; Lange, 2004) . These biological effects include changes in hormone secretion, uptake of small molecules, activation of ion channels, and stimulation of cytoplasmic enzymes such as MAPK, PKA, and PI3K, which cannot easily be explained by the transcriptional activities of the ERs and PRs (reviewed in Levin, 2003; Moe-Behrens et al., 2003; Lange, 2004) . The responses, which occur in seconds to minutes, have popularly been termed 'nongenomic'. However, because many activated kinases translocate to the nucleus and modify and activate transcription factors, including steroid receptors, this pathway can ultimately regulate gene expression. In fact, the ability of growth factors to activate intracellular protein kinases and induce transcription of critical immediate-early and cell cycle-regulating genes has important biological consequences, including cell proliferation (Weber et al., 1997) . In this fashion, the steroid and growth factor signaling pathways can converge to regulate genes such as c-fos, c-myc, and cyclin D1, which play a role in cell proliferation (Weber et al., 1997; Kerkhoff et al., 1998) .
Rapid E2 actions -localization of relevant ER forms
One critical question in determining the mechanism for rapid E2 effects has been the cellular location of the relevant ER. To date, few rapid actions of E2 have been noted in the absence of expression of the cognate ERa or ERb 'nuclear' receptors, as demonstrated in ER genedisrupted animals (Couse and Korach, 1999) , or by transfection of ER expression vectors into ER-negative Chinese hamster ovary (CHO) or rat fibroblast cell lines (Razandi et al., 1999, 2003a, b) . Some signaling and pharmacological studies in brain tissue suggest the existence of membrane-associated receptors related, but not identical to, the bone fide ERa and ERb proteins (reviewed in Toran-Allerand, 2004) . Others have suggested that the G-protein-coupled receptor GPR30 plays a critical role in E2 activation of MAPK in the absence of nuclear ER expression by causing the release of heparinbound EGF that transactivates the EGF-R (Filardo et al., 2000) . However, the isolation, cloning and confirmation of authentic novel membrane ERs has yet to be accomplished, and antisense inhibition of GPR30 in MCF7 breast cancer cells that express endogenous ERa had no effect on E2 stimulation of cell proliferation (Ahola et al., 2002) . In most tissues, it appears that a novel form of ER does not have to be proposed, and a small pool of the cognate 'nuclear' receptors are found in the cytoplasm, and are often associated with membrane structures by cell fractionation and immunohistochemistry (Gu et al., 1999; Razandi et al., 1999; Watson et al., 1999; Martin et al., 2000) .
Because the ERs do not contain transmembrane or integral membrane motifs, this functional association with the membrane may occur by association of the receptors with other integral membrane molecules, or adaptor proteins that can interact directly with such molecules. ERs can interact with caveolin-1 and are localized to caveolae raft domains isolated from plasma membranes of endothelial cells (Schlegel et al., 1999; Razandi et al., 2002) . Imaging analysis of endogenous ERa in MCF7 breast cancer cells shows a pool of receptors near the plasma membrane (Song et al., 2002) . In the presence of E2, there is increased membrane ruffling and increased association of ERa on the extending filipodia. Both processes are eliminated in the presence of antiestrogens, but it is not known how or if the liganded ERa causes ruffling directly. ERa forms that have been engineered to remain in the cytoplasm and/or to be transcriptionally inactive can still stimulate intracellular signaling pathways such as MAPK and stimulate DNA synthesis in ER-negative fibroblast cells (Castoria et al., 1999) . Mutations that diminish the cytoplasmic/membrane localization severely impair these responses in other ER-negative model systems (Razandi et al., 2003a) . Others have reported that transcriptionally inactive and cytoplasmic forms of ERs and the androgen receptor are fully functional in activating ERK signaling through a Shc/c-Src-mediated pathway and inhibiting apoptosis in bone cells (Kousteni et al., 2001) . Complete nuclear targeting of the receptor proteins eliminated the responses. In aggressive breast cancer, high levels of truncated metastatic tumor antigen 1 (MTA1) protein was found; this protein sequesters ERa away from the nucleus and strongly reduces E 2 -activated transcription, yet promotes increased E2-stimulated MAPK signaling . The full extent of membrane-initiated signaling by E 2 /ER, or dependence on other signaling molecules remains to be defined, and the in vivo significance is incompletely understood. However, important biological responses can clearly be initiated by ER outside the nucleus in model systems.
Intracellular signaling partners of ER
Regardless of the precise membrane location of ERa or ERb, there appear to be several mechanisms and signaling partners through which E2 activates intracellular signaling pathways. For example, ERa -but not ERb or PR -interacts directly with the P85 regulatory subunit of PI3K, and this association is required to stimulate E2 signaling through this pathway in endothelial and breast cancer cells (Simoncini et al., 2000; Castoria et al., 2001; Sun et al., 2001) . E2 stimulation of PI3K has also been shown to require c-erbB2 signaling in some breast cancer cell lines (Stoica et al., 2003) . ERs have also been proposed to couple directly or functionally with G proteins Gaq and Gai, leading to downstream signaling through PKC, PLC, and c-Src (reviewed in Levin, 2003) . ERa association with the adaptor molecule Shc occurs within 3 min of E2 treatment in MCF7 and long-term estrogen-deprived (LTED) MCF7 cells, resulting in Shc and MAPK phosphorylation (Song et al., 2002) . The phosphorylation responses to E2 were inhibited by antiestrogens and by pharmacological inhibitors of c-Src. Recent studies in which Shc expression was eliminated in MCF7 breast cancer cells by small inhibitor RNA molecules suggest a critical role for Shc in localizing ERa to the membrane, and that a ternary complex can exist in breast cancer cells between Shc, ERa and the insulin-like growth factor-1 receptor (IGF-1R) (Song et al., 2004) . Elimination of any of these molecules abrogates the ability of E2 to stimulate MAPK phosphorylation (Song et al., 2004) . The authors postulate that Shc serves as a translocator for ERa by binding to the receptor and then carrying it to the Shc-binding sites of IGF1-R that are located on the cell membrane. Shc knockdown does not eliminate E2-induced membrane ruffling; but because both ERa and IGF-1R also associate with the P85 subunit of PI3K, E2 signaling for ruffling might still occur through this pathway. It is not known if Shc and ERa can associate with other growth factor receptors in this fashion. Recently, the adaptor protein p130Cas has also been demonstrated to be present in a multimolecular complex with ERa, c-Src, and PI3K in T47D breast cancer cells (Cabodi et al., 2004) . Formation of the complex occurs within 3 min with E2 treatment, and is dependent on c-Src kinase activation. Furthermore, depletion of Cas by siRNA both slowed and diminished stimulation of cyclin D1 by E2. Thus, the ERa can exist in multiple signaling complexes, including molecules that are critical for cell proliferation and survival, and at least some of these modify E2 responses.
ER regions required for intracellular protein-protein associations and rapid biological responses
The regions of ER that are required to mediate these intracellular signaling events are not completely defined and may differ depending on the particular pathway activated. Expression of only the ERa LBD, which binds E2, is sufficient for stimulation of MAPK in bone cells (Kousteni et al., 2001) , and targeting the LBD domain of ERa to the membrane is sufficient for full binding of steroid at the membrane and for E2 activation of MAPK at a level comparable to that induced by full-length receptor in CHO cells (Razandi et al., 2002) . Similarly, targeting the C-terminal of ERa to the membrane of ER-negative breast cancer cells results in E2-stimulated, c-Src-dependent matrix metalloprotein activation, liberation of heparin-bound EGF, and subsequent EGF-R activation (Razandi et al., 2003b) . In contrast, only the N-terminal A/B domain of ERa is required and sufficient to associate with Shc in MCF7 breast cancer cells (Song et al., 2002) , although the full-length receptor would be expected to be required for E2-mediated responses. Similarly, only the DBD and hinge domain of ERa and ERb are required to interact with STAT5 in mammary epithelial cells, but it is unclear if the critical interaction occurs in the cytoplasm or nucleus (Bjornstrom et al., 2001) .
Many signaling molecules, including Shc and c-Src, contain SH2 (Src homology 2) domains capable of associating with phosphorylated tyrosine residues. ERa has been reported to be phosphorylated on tyrosine 537 by c-Src or other enzymes, although it has been difficult to demonstrate significant levels of phosphorylated receptor in cells (Arnold and Notides, 1995; Migliaccio et al., 1996) . Mutation of Y537 to phenylanaline has no effect on the ability of human ERa to associate with Shc (Song et al., 2002) , and mutation of the equivalent residue in mouse ERa does not interfere with E2 stimulation of the STAT-activated casein promoter in mouse mammary cells (Bjornstrom and Sjoberg, 2002) . Because Shc associates with ERa via its PTB domain, which would require some phosphorylated residue, the ER-Shc association may occur through an intermediary protein, as has been proposed for ERa and c-Src (Wong et al., 2002) .
Rapid cytoplasmic signaling via PR
Ligand-bound PR can also rapidly stimulate intracellular signaling pathways such as MAPK, and in tissues and cells such as breast cancer cells is proposed to do so via pools of cytoplasmic and/or membrane-associated cognate receptors (reviewed in Lange, 2004) . The only known exception is in fish oocytes, in which a novel family of G-protein coupled receptors bind the steroid and promote oocyte maturation in the absence of expression of any nuclear receptor form of PR (Zhu et al., 2003) . Breast cancer cells transfected with the fish membrane PR demonstrated progestin-induced MAPK activation and inhibition of cAMP production that was pertussis toxin-sensitive. Mammalian homologues of these genes have been identified by sequence analysis, but the potential expression and biological activities of such proteins and any implication for steroid actions in mammalian tissues is presently unknown.
In T47D breast cancer cells, ligand-activated cognate PRs rapidly promote the translocation of active STAT transcription factors to the nucleus, association of Stat5 with phosphotyrosine-containing proteins, and tyrosine phosphorylation of JAK2 and Shc. Richer et al., 1998) . Progestin treatment also increases levels of the STAT proteins and potentiates the effects of EGF by upregulating EGF-R, c-erbB2, and c-erbB3 receptors (presumably by genomic mechanisms), and by enhancing EGF-stimulated tyrosine phosphorylation of signaling molecules known to associate with activated receptors. Furthermore, progestins potentiate EGFstimulated p42/p44 mitogen-activated protein kinase (MAPK), p38 MAP kinase, and JNK activities, thus potentially sensitizing breast cancer cells to the effects of growth factors (Lange et al., 1999) . Unlike ERs, the PRs have not to date been found in a wide variety of complexes with intracellular signaling molecules, and appear to exert their actions primarily by direct association with c-Src, as discussed below.
Functional and direct interactions of ER and PR with c-Src
One of the most fundamental players for the integration of steroid and growth factor signaling may be the cellular tyrosine kinase molecule c-Src. Data from many laboratories now suggest that functional c-Src is required for intracellular signaling and cell proliferation initiated by both growth factors and steroids. Cooverexpression of both kinase-active EGFR and c-Src is required for transformation and growth of C3H101/2 cells, and there is a direct physical association between the EGFR and c-Src Tice et al., 1999) . Overexpression of c-Src induces two specific tyrosine phosphorylations on the EGFR, at Y1101 and Y845 in murine fibroblasts and breast cancer cells, and phosphorylation at Y845 is required for EGF-stimulated growth Biscardi et al., 2000) . Mutant EGFR that cannot be phosphorylated on tyrosine 845 (Y845F) cannot support EGF-mitogenic signaling initiated by EGF, several G-protein-coupled receptors, or ER (Biscardi et al., 2000) . Human breast tumors and breast cancer cells, both ER and PR positive and negative, contain amplified levels of c-Src compared to normal mammary cells, typically with co-overexpression of at least one HER family member (EGFR, c-erbB2. c-erbB3, or c-erbB4) . However, increased expression of HER1, the EGF-R, does not occur in combination with ER or PR Levin, 2003) . et al. (1996, 1998) first demonstrated that E2 stimulated both MAPK and p60 c-Src activity in breast cancer cells, and that a physical association between ER, PR, and c-Src could occur. Microinjection of kinasedead c-Src into breast cancer cells prevented stimulation of cell proliferation by either E2 or progestins (Castoria et al., 1999 ). An essential role for c-Src in nongenomic actions of steroid receptors was suggested in studies in embryonic fibroblasts derived from SrcÀ/À mice, which failed to support rapid activation of the MAPK pathway in response to ER, whereas wild-type c-Src þ / þ cells did (Kousteni et al., 2001) . Several investigators have shown that c-Src kinase activity is required for E2-bound ERa to stimulate MAPK and PI3K activity in breast cancer and bone cells (Migliaccio et al., 1996; Castoria et al., 2001; Song et al., 2002; Cabodi et al., 2004) , and to stimulate the activation of metalloproteases and release of heparin-bound EGF in breast cancer cells (Razandi et al., 2003b) . Human PR-B stimulation of MAPK activity has recently been shown to require functional and physical association with c-Src (Boonyaratanakornkit et al., 2001) , and progestin activation of MAPK in breast cancer cells is proposed to require both ER and c-Src association (Migliaccio et al., 1998) .
ER and PR functional activity and association with c-Src

Migliaccio
Physical interactions between ER, PR, and c-Src
Ligand-dependent multimolecular complexes containing c-Src and ERa or ERb, together with varying combinations of PI3K and adaptor scaffold proteins such as P130 Cas and the recently described MNAR (modulator of nongenomic activity of the ER) have been found in breast and prostate cancer cells (Castoria et al., 1999; Migliaccio et al., 2000; Wong et al., 2002; Cabodi et al., 2004) . There is at least some degree of specificity to complex formation, as focal adhesion kinase (FAK) is not associated with complexes containing ER, c-Src, and p130Cas (Cabodi et al., 2004) . At present, our understanding of which molecules can coexist in such complexes, or the rank order of molecular interactions and hierarchy of formation of these complexes is incomplete.
In addition to these multimolecular complexes, direct interactions between c-Src and ERa and PR (Figure 2 ) have now been demonstrated (Migliaccio et al., 1998; Boonyaratanakornkit et al., 2001) . The Src family of kinases are basally inactive because the catalytic domain is constrained in an inactive state through intramolecular interactions. In the inactive state, the Src homology 2 (SH2) binds to a C-terminal phosphorylated tyrosine, and the neighboring Src homology 3 (SH3) domain binds to a proline-rich linker region elsewhere in the molecule. Catalytic activation requires release of the constraints by c-Src binding to other phosphorylated tyosine residues (to SH2) or proline-rich motifs (to SH3). Human PR contains a proline-rich (PXXP) motif in its N-terminus that binds directly to SH3 domains in c-Src and related kinases in a liganddependent manner (Boonyaratanakornkit et al., 2001) . Mutation of this motif abolished binding of purified PR-A and PR-B to c-Src or the related kinase Hck in vivo. In addition, progestins activated c-Src in PR-null MCF12A cells transduced with wt PR but not PXXP-mutant PR adenoviruses. The same mutation prevented cellular activation of c-Src or MAPK by PR, but mutation of the DBD of PR had no effect. These data suggest that MAPK stimulation by ligand-bound PR proceeds through activated c-Src followed by Shc, Grb-2, and Sos binding and activation. A similar proline-rich sequence in androgen receptor has also been shown to interact with c-Src in vitro (Migliaccio et al., 2000) .
ERa has been shown to interact with the SH2-domain of c-Src (Migliaccio et al., 2000; Boonyaratanakornkit et al., 2001; Ballare et al., 2003) , and a phosphorylated tyrosine at position 537 in the LBD of human ERa is proposed to be a required structural determinant for this interaction (Migliaccio et al., 2000; Barletta et al., 2004) . However, phosphorylation of this residue has been difficult to demonstrate in cells, and the enzyme responsible for phosphorylation of this tyrosine in a VVPLYDLL motif is unknown, suggesting that the modification may only be important in specific cellular contexts or in defined signaling pathways. Phosphorylation of the mouse ERa homologue of Tyr 537 (Tyr 541) is not required, for example, for E2-ER stimulated, Statmediated b-casein promoter activity (Bjornstrom and Sjoberg, 2002) , or for human ERa interactions with Shc, which occur in spite of a mutated (ERaY537F) receptor (Song et al., 2002) .
It has also been proposed that ERa binding could be mediated or stabilized by binding to adaptor proteins, and one such candidate, called moderator of nongenomic activity of ER (MNAR), has been identified from a breast cancer cell library (Wong et al., 2002) . MNAR associates with ligand-bound ERa, ERb, AR, and GR through LXXLL motifs, similar to those of nuclear receptor coactivators, and binds to the c-Src SH3 domain via a proline-rich region (Barletta et al., 2004) . This interaction leads to stimulation of c-Src enzymatic activity and activation of the MAPK pathway, and mutation of the first PXXP proline motif prevents MNAR-induced c-Src activation. It is proposed that MNAR brings the ER into proximity with c-Src and helps enhance activation of c-Src by providing more effective interaction of ER and c-Src as well as by relieving c-Src inhibition through binding to the SH3 domain. Phosphorylated Y537 peptides, but not unphosphorylated peptides, inhibited binding of cell-free translated ERa to the isolated c-Src SH2 domain, but the effect of mutation of this residue on ERa nongenomic activity has not been investigated. MNAR activity does not appear to be required for PR nongenomic activity (cited in Lange, 2004) . MNAR can also act as a coactivator of nuclear receptor transcription, and both PXXP and LXXLL domains are required for that activity. ERa transcriptional stimulation by MNAR requires MNAR binding to ER, c-Src activity, ER Y537 phosphorylation, and the integrity of ERa Serines 104, 106 and 118 (Barletta et al., 2004) . The authors hypothesize that ERa activation of c-Src kinase signaling cascades can subsequently activate ER (and its coactivators) in a ligand-independent manner and synergize at the level of chromatin. Although ERb has been demonstrated to bind to MNAR, the important motifs required for this interaction have not been defined. ERb has an amino-acid motif around tyrosine 507 that is identical to human ERa Y537, but it is not known if this residue can be phosphorylated, or contributes to ER-signaling interactions. ER interaction with c-Src has also been proposed to play a critical role in PR and androgen receptor stimulation of c-Src activity in Cos-7 and bone cells by formation of ER-PR or ER-AR heterodimers, and progestin or androgen effects in these cells can be repressed by antiestrogens (Migliaccio et al., 2000; Kousteni et al., 2001; Ballare et al., 2003) . In the case of PR, it is proposed that activation of c-Src and the MAPK pathway by progestins depends upon the presence of unliganded ERa phosphorylated at tyrosine 537, which interacts with PR-B via two domains that flank but do not include PR's proline-rich sequence (Ballare et al., 2003) . These data are in direct contrast to studies which find that ER is not needed for PR effects and that the PXXP region is required (Boonyaratanakornkit et al., 2001) . Although the reasons for these discrepancies must be resolved, it is possible that overexpression of steroid receptors in COS-7 cells leads to concentration-dependent formation of different signaling complexes that depend on the presence of other signaling and adaptor molecules. It remains to be determined if such crosstalk between steroid receptors for rapid steroid effects plays an important role in vivo.
Implications for growth of cancer cells
Observations from tamoxifen-resistant breast cancer For many years, use of the antiestrogen tamoxifen has been an important adjuvant treatment for ER-positive breast cancer. However, some tumors never respond to tamoxifen, and other tumors gradually develop resistance to the drug (reviewed in Clarke et al., 2001) . In MCF-7 breast cancer cells that exhibit induced resistance to tamoxifen, an alternative basal growth regulatory pathway is established through the increased levels of EGF-R and c-erbB2, increased basal phosphorylation of EGFR-c-erbB2 and EGFR-cerbB3 dimers, and basal activation of an EGFR/c-erbB2/MAPK signaling cascade (Knowlden et al., 2003) . Similar pathways are activated in breast cancer cells resistant to the 'pure' antiestrogen faslodex (McClelland et al., 2001) . Human breast tumors with acquired resistance to tamoxifen often have increased expression of c-erbB2 and/or EGF-R (Nicholson et al., 1999) . Investigators have identified, by retroviral-insertion mutagenesis, the BCAR1 gene as a genetic factor that could lead to antiestrogen resistance in vitro and in transfected breast cancer cells in culture . This gene was subsequently identified as p130Cas, and analysis of this protein in a large series of primary breast tumors showed that high Cas levels were associated with more rapid disease occurrence and a greater risk for intrinsic antiestrogen resistance (van der Flier et al., , 2001 ). p130Cas has recently been shown to associate with and stimulate c-Src activity (Riggins et al., 2003) . Thus, one interpretation is that increased signaling through growth factor pathways, including EGF-R, c-erbB2, and c-Src reduces the reliance on estrogen-sensitive proliferation, or may even make such pathways irrelevant in breast cancer cells. It should be noted, however, that tamoxifen is not a 'pure' antiestrogen, and that some genes are still stimulated in the presence of the drug, including those increased by E2 as well as those stimulated only by tamoxifen (Frasor et al., 2004) .
Common, complimentary or predominant pathways?
In many steroid-dependent cancers, both steroids and growth factor stimulate cell proliferation and G1/S cell cycle progression (reviewed in Sutherland et al., 1998; Levin, 2003; Lange, 2004) . The demonstration that IGF-1, EGF and HER family members can activate steroid receptor transcriptional activity in the absence of ligand, and that steroids and growth factors rapidly stimulate the same intracellular signaling pathways, suggests that there may be some common stimulated pathways for cell proliferation and tumor growth. Interestingly, experiments with several pharmacological inhibitors as well as dominant-negative signaling molecules suggest that the MAPK, PI3K, c-Src and STAT pathways all play critical roles in mediating both steroid and growth factor stimulation of cancer cells (Castoria et al., 1999 (Castoria et al., , 2001 Yue et al., 2002; Kloth et al., 2003; Stoica et al., 2003; Yamashita et al., 2003) . Both steroids and growth factors stimulate expression of several genes critical for cell cycle progression, including cyclin D1, cyclin E, and cdk inhibitors p21 and p27, and ongoing expression profiling of breast cancer cells and breast tumors may provide some information on larger subsets of genes that are common for both steroid and growth factorstimulated growth (Sotiriou et al., 2003; Frasor et al., 2004 ).
It appears from such studies that many signaling pathways and genes contribute to proliferation, and that in at least certain contexts suppression of any of these could repress cell growth. The relative hierarchy of these pathways -which are most important for progression through the cell cycle and proliferation, and thus candidates for targeted therapy -are yet to be determined. Steroid and growth factors both contribute to maximal proliferation of steroid-dependent cells, and in normal uterine and mammary cells and even some cancer cells removal of one pathway prevents full functioning of the other. Could each treatment help cells reach a critical 'threshold' level of common critical signaling molecules, or are there both common and complementary pathways involved? Is the transcriptional activity of the steroid receptors required? Clearly, ligand-directed steroid-receptor-dependent transcription might provide one complimentary pathway to stimulate cell growth. There is both independent activation and synergy of ER and PR transcription in the presence of ligand and growth factors, but it is not yet known if growth factor activation of steroid receptor activity will stimulate the same gene profile as growth factors independent of steroid receptors, or steroid receptors activated only by ligand.
Although some investigators have found that transcriptional activity and nuclear localization of ER and PR are not required for the proliferative effects of steroids in fibroblast model systems (Castoria et al., 1999) ; others have found that nongenomic activity of ER and MAPK simulation is insufficient to stimulate DNA synthesis in endometrial adenocarcinoma cells (Singleton et al., 2003) . Data from tamoxifen-resistant breast tumors and breast cancer cells show that initial steroid dependence can be overcome by increased signaling through growth factor-mediated pathways. Thus, one likely possibility is that steroids contribute to common pathways of growth factor stimulation, although additional steroid stimulation of specific pathways that are complementary to those stimulated by growth factors cannot be ruled out, and that these common pathways may be overall most critical for cell proliferation. It has been proposed that that steroids 'prime' breast cancer cell growth by stimulating intracellular signaling pathways such as MAPK and STATS, and making growth factor treatment more effective in steroid-dependent cancer (Lange et al., 1999) . Could steroid receptors also serve as an internal restraint to signaling through cytoplasmic pathways, requiring two signals (steroid and growth factors) for maximal proliferation? In this case, the loss of steroid receptors, along with increased cellular expression of other signaling molecules, would contribute to the flow of cytoplasmic signals through growth factor-stimulated pathways. Cellular stoichiometry between the various receptors, and between groups of signaling molecules may then be critically important, and overall cell proliferation thus determined by cell context and the endogenous hormonal milieu.
Summary
At one level, functional crosstalk between the steroids and growth factors can be explained by steroid regulation of the growth factors or their receptors, or by growth factor activation of the steroid receptors via ligand-independent pathways involving growth factorstimulated enzyme cascades. The demonstration that steroids rapidly activate enzymatic signaling pathways, and that ligand-bound receptors form multimolecular signaling complexes, including association of ER and PR with IGF-1R, Shc, p85 regulatory subunit of PI3K, p130Cas, and c-Src, suggests that direct communication between these signaling pathways and molecules occurs. Steroid receptors thus perform dual functions, acting in the nucleus to stimulate gene transcription and in the cytoplasm to activate protein kinases, which themselves may stimulate receptor activity. Functional crosstalk between steroid receptors and tyrosine-kinase receptors of the growth factor family occurs in both the cytoplasm and nucleus of steroid-dependent cells. These interactions may allow for therapeutic manipulations of specific pathways, perhaps equally effectively for treatment of steroid-dependent or steroid-independent cancers arising from these cells.
